Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now

Executive Summary

FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.

Advertisement

Related Content

Pfizer On Lung Cancer: "We Need To Have Single-Agent Avelumab"
Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
Merck Confident About Keytruda/Chemo Combo May Date With FDA
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
AACR In Review: IDO Pushes Ahead, CTLA-4 Combo Lags Behind
Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel